Nathaniel David

Over the last decade, Nathaniel David has co-founded five technology companies that have collectively raised more than $700 million in financing. Teaming with ARCH in 2009, Dr. David is building new companies that create disruptive technologies to address global-scale problems. During the last year of his doctoral work (1998) at the University of California, Berkeley, he co-founded Syrrx, which was acquired for $270M in 2005. The first drug to arise from Syrrx’s research programs (a DPP4 inhibitor for the treatment of type 2 diabetes) was recently approved in Japan and is awaiting regulatory approval in the EU and in the US. This drug, ALOGLIPTIN, is expected to have worldwide peak sales in excess of $2B. In 2003, Dr. David co-founded Achaogen, an antibiotic discovery company developing a potent anti-gram negative antibiotic now in Phase II clinical development. Teaming up with a group of former Amgen employees, he co-founded Kythera Biopharmaceuticals where he served for four years as Chief Science Officer, a role in which he managed all pre-clinical drug discovery efforts. During his tenure, two first-in-class therapies (ATX-101 and ATX-104) entered human clinical trials. ATX-101 is currently commencing Phase III clinical trials in 10 counties. In the clean technology arena, Dr. David is co-founder of Sapphire Energy, a biotechnology-driven energy company developing next generation fuels that are 100% compliant with the current fuel infrastructure, and Kilimanjaro Energy, a company developing energy efficient methods to harvest and concentrate atmospheric CO2 for use in the production of liquid transportation fuels with dramatically reduced carbon footprints. Dr. David holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, and aesthetic medicine. He serves on the board of directors of Kilimanjaro Energy, Kythera Biopharmaceuticals, and Sapphire Energy is a member of the board of trustees of the University of California Foundation. Dr. David was named one of the Top 100 innovators in the world under 35 by the MIT Technology Review. Dr. David holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard College.

Doing good things that matter.

baking, imitating accents,